In 2021, dapagliflozin was granted approval in Europe for the treatment of adults with CKD [19] irrespective of diabetes status, becoming the first sodium-glucose transporter 2 (SGLT2) inhibitor with this indication. Here, SLC5A2 is linked to chronic kidney disease.